It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Looking for quick cash? Here are effective ways to access cash quickly, ensuring you meet your financial needs without delay.
25,089 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
U.S. stocks faced a bifurcated session as analysts issued fresh price targets and ratings on key names, signaling the...
As market conditions shift in 2026, investors are weighing cheaper covered call ETFs against XYLD. Four funds stand o...
NVIDIA stock has surprised some by not rallying in 2026 despite booming AI demand. This article breaks down why the s...
Are you trying to decide between gold miners and silver miners? This guide breaks down GDX vs SLVP, highlighting cost...
Markets are volatile, but corrections can reset prices, boost disciplined investing, and strengthen long-term strateg...
The spotlight isn’t only on SCHD. Schwab’s international dividend ETF SCHY is quietly stealing the show for investors...
BlackBerry reports three profitable quarters powered by QNX, but Wall Street shows little enthusiasm as shares hover ...
As the infrastructure megatrend gathers steam, a single ETF could anchor your 2026 strategy. Learn which fund stands ...
Public financing is reshaping homebuilding profitability, with front-end agreements dictating costs and returns as di...
Oil jumped sharply in March 2026, but USOI investors faced capped upside and ongoing credit risk. The piece explains ...
Casey’s General Stores posted stronger fuel margins and a growing Rewards base, lifting investor optimism. Analysts c...